2 news items
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
SYRE
15 May 24
in the upcoming months."
Prior to her current role at Aspira, Dr. Milligan served as the Head of Research
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SYRE
9 May 24
placement of equity securities.
Research and Development (R&D
- Prev
- 1
- Next